<DOC>
	<DOCNO>NCT01657266</DOCNO>
	<brief_summary>The purpose study evaluate efficacy safety ophthalmic solution PRO-155 patient post phacoemulsification .</brief_summary>
	<brief_title>Efficacy Safety PRO-155 Versus Nevanac Post Phacoemulsification</brief_title>
	<detailed_description>Postsurgical inflammation inevitable condition cataract surgery . The use non-steroidal anti-inflammatory drug safe option treat ocular inflammation . This phase II randomize double-blind clinical trial . The aim compare evaluate efficacy safety two ophthalmic solution patient post phacoemulsification . Patients randomize receive either PRO-155 Nevanac 60 day .</detailed_description>
	<mesh_term>Cataract</mesh_term>
	<mesh_term>Ophthalmic Solutions</mesh_term>
	<mesh_term>Nepafenac</mesh_term>
	<criteria>Patients older 18 year require cataract surgery Both gender Provide inform consent Normal Laboratory result Patients visual acuity 20/40 less contralateral eye surgery Patients transsurgical complication Patients cataract &gt; NC4 , C4 P4 classify system LOCS Patients active corneal pathology Patients steroidal treatment ( topic , systemic inhale ) 14 day prior surgery NSAIDs 7 day surgery ( except lowdose aspirin ) Patients IOP &lt; 5 &gt; 21 mmHg Patients ocular pain , cellularity flare moment selection Patients ocular exfoliation , trauma inflammatory disease Patients diabetic retinopathy need treatment uncontrolled diabetes mellitus Patients plan cataract surgery contralateral eye 14 day surgery study eye Patients history hypersensitivity contraindication drug use study Patients anticoagulant treatment Contact lens user Pregnant patient , risk pregnancy breastfeed Patients without birth control treatment Patients active toxicomanies ( alcoholism , cigarette , cannabis others ) Patients participate clinical trial last 90 day Legal mentally disable patient could give informed consent Patients comply study requirement</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2014</verification_date>
</DOC>